EcoDrugPlus

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSSDUG00000023823
Gene Symbol: LOC111239914
2 Cross references
69 Possible Orthologues:

Voltage-Dependent N-Type Calcium Channel Subunit Alpha-1b-Like

Ensembl ID : ENSSDUG00000009992
Gene Symbol: LOC111227530
3 Cross references
219 Possible Orthologues:

Voltage-Dependent T-Type Calcium Channel Subunit Alpha-1g-Like

Ensembl ID : ENSSDUG00000009366
Gene Symbol: LOC111219652
2 Cross references
196 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSSDUG00000017368
Gene Symbol: LOC111216550
2 Cross references
190 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSSDUG00000003279
Gene Symbol: LOC111233238
3 Cross references
167 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSSDUG00000007583
Gene Symbol: LOC111227134
3 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSSDUG00000003265
Gene Symbol: LOC111233249
3 Cross references
182 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-7 Subunit-Like

Ensembl ID : ENSSDUG00000003295
Gene Symbol: LOC111233246
4 Cross references
184 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-1-Like

Ensembl ID : ENSSDUG00000002864
Gene Symbol: LOC111224485
3 Cross references
226 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSSDUG00000003158
Gene Symbol: XDH
3 Cross references
208 Possible Orthologues:

Ensembl ID : ENSSDUG00000013556
Gene Symbol: -
Cross references: -
163 Possible Orthologues:

Ensembl ID : ENSSDUG00000011371
Gene Symbol: -
Cross references: -
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).